Welcome to the newly redesigned ASHClinicalNews.org! As you navigate the site, please send any feedback/issues to [email protected].
Harnessing the Power of Collaboration
ASH Clinical News spoke with Richard Pazdur, MD, director of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), about the scope of the new center and its efforts to accelerate...
Online Exclusives
AMA Adopts New Policies on Immigration Reform, Drug Pricing Transparency
At the American Medical Association’s (AMA) annual meeting, the organization’s House of Delegates voted to adopt new policies on several health-care topics, including protecting...
Phase III Trials of Vadastuximab Talirine Discontinued Amid Safety Concerns
Seattle Genetics, Inc. announced the discontinuation of the phase III CASCADE trial of vadastuximab talirine (also known as SGN-CD33A) in older patients newly diagnosed...
News
From the Blood Journals
Rates of Myeloid Neoplasms in Patients With Unexplained Cytopenias
Patients with unexplained cytopenias may never receive a definitive diagnosis, or may eventually be classified as having myelodysplastic syndromes (MDS, a myeloproliferative neoplasm ...
Enoxaparin Increases Risk of Intracranial Hemorrhage in Patients With Glioma
Venous thromboembolism occurs in approximately one-third of patients with glioma, but the decision to treat patients with anticoagulation is complicated by the risk for...
Latest Videos
Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML
Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell...
Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL
Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas
Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
On Location
Mixed Results in Trials of Momelotinib Versus Ruxolitinib for Myelofibrosis
The investigational JAK1/2 inhibitor momelotinib was active in the treatment of myelofibrosis (MF) in phase...
BFORE Trial: Bosutinib Could Be a “Welcome” New Treatment Option for Chronic-Phase CML
Treatment with the dual SRC/ABL tyrosine kinase inhibitor bosutinib was associated with a higher major...
Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy Is Safe, Effective in Older Patients With ALL
In February 2017, the U.S. Food and Drug Administration granted inotuzumab ozogamicin priority review for...
Early Results from CAR T-Cell Therapy Trial for Myeloma Show “Encouraging” Response Rates
In an ongoing, phase I trial of chimeric antigen receptor (CAR) T-cell therapy in patients...
Minimizing VTE Risk in Myeloma Patients Receiving Immunomodulators
Patients with myeloma who receive treatment with immunomodulatory drugs (IMIDs) such as lenalidomide and thalidomide...
Is Denosumab a Safer Alternative to Zoledronic Acid in Newly Diagnosed Myeloma?
Patients with multiple myeloma (MM) can experience osteolytic bone disease that is typically treated with...
Latest Headlines
ASH Directions
AML Matters Summit, ASH President Participates in LLS Panel Discussion, and more
AML Matters Summit Continues Across U.S.
AML Matters is a free educational program designed to provide guidance to health-care professionals on the optimal diagnosis and...
Marching for Science, New Opportunities for International Collaboration, and more
Marching for Science
The first March for Science, which took place Saturday, April 22, 2017, in more than 600 locations around the world, drew hundreds...
Remembering Neil Abramson, MD, AACC Announces Clinical Chemistry Trainee Council Educational Initiative, and more
Remembering Neil Abramson, MD (1937-2017)
Neil Abramson, MD, a hematologist/oncologist who served as a Blood Special Section Editor from 2008-2012, passed away at the age...
ASH 2017 Bridge Grant Awards, Hematologists Receive Stand Up To Cancer 2017 Innovative Research...
ASH Announces 2017 Bridge Awards
The American Society of Hematology (ASH) announced the names of five investigators who have received the latest round of ASH...
ACS Announces Lane W. Adams Quality of Life Award Winners, 2017 Eric G. Neilson,...
ACS Announces Lane W. Adams Quality of Life Award Winners
The ACS honored six cancer caregivers with the Lane W. Adams Quality of Life Award,...
Show Me the Money? Show Us the Data!
How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers?
The merits and cautions of data sharing have long been a...
Uncommon Presentations, Uncommon Cancers
In this column, Beth Faiman, CNP, PhD, reviews the 5th edition of the Textbook of Uncommon Cancer.
Have you read any hematology-related books recently? Let...
Agent Orange and Hematologic Malignancies: The Fog of War Still Hovers
More than 40 years after the Vietnam War, the fog of Agent Orange hangs thick over veterans and those providing their medical care. Aging...
